BIO
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

996
Mkt Cap
$9.19B
Volume
0.00
52W High
$387.99
52W Low
$211.43
PE Ratio
28.95
BIO Fundamentals
50D MA
$295.04
Beta
0.87
Avg. Volume
217,825.67
EPS (Annual)
-$65.36
P/B
1.29
Rev/Employee
$333,311.69
Loading...
Loading...
News
all
press releases
Envista (NVST) Earnings Expected to Grow: Should You Buy?
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3d ago
News Placeholder
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on...
Business Wire·9d ago
News Placeholder
Aurora Cannabis (ACB) Soars 6.2%: Is Further Upside Left in the Stock?
Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·17d ago
News Placeholder
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
Zacks·2mo ago
News Placeholder
Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.
Zacks·3mo ago
News Placeholder
New Strong Sell Stocks for July 10th
BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.
Zacks·4mo ago
News Placeholder
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Zacks·4mo ago
News Placeholder
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Zacks·6mo ago

Latest BIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.